© 2002 European Society of Cardiology
Increased myocardial expression of osteopontin in patients with advanced heart failure
a Department of Medicine/Cardiology, German Heart Institute Berlin Augustenburger Platz 1, D-13353 Berlin, Germany
b Department of Pathology, Charité, Humboldt-University Berlin Schumannstraße 20-21, D-10117 Berlin, Germany
* Corresponding author. Tel.: +49-30-4593-2400; fax: +49-30-4593-2500. E-mail address: graf{at}dhzb.de
 |
Abstract |
|---|
The expression of the adhesion protein osteopontin (OP) is associated with cardiac hypertrophy and is significantly increased after transition to heart failure in experimental animal models. We, therefore, hypothesized that OP could be upregulated in heart failure in humans. In the present study, we investigated the expression of OP in myocardial biopsies obtained from patients with heart failure due to dilated cardiomyopathy (mean LVEF = 30.3±4.4%, mean±S.D., n = 10, group A) compared to patients with a normal left-ventricular ejection fraction (mean LVEF = 61±11.2%, n = 9; group B). Myocardial immunoreactivity for OP was examined using two different antibodies against OP. The expression of cardiac myocyte OP was significantly upregulated in group A in comparison to group B (P<0.0001). Both groups also displayed OP immunoreactivity in non-myocytes, including vascular smooth muscle cells and cardiac fibroblasts (P = not significant). Statistical analysis revealed a significant correlation of increased OP immunoreactivity in cardiac myocytes of patients with impaired left ventricular function, assessed by hemodynamic data (LVEF, RVEF, LVESVI, LVEDVI and LVEDP, R = –0.828, –0.671, 0.751, 0.685 and 0.461, respectively; all P<0.05). Furthermore, OP expression correlated with cardiac myocyte hypertrophy (mean diameter 21.0±1.8 µm in group A and 16.6±2.1 µm in group B; P<0.0001). In conclusion, the present study indicates, that factors and/or mechanisms involved in heart failure in patients with dilated cardiomyopathy, lead to induction of OP expression in humans.
Key Words: Dilated cardiomyopathy • Myocardial biopsy • Adhesion molecules • Heart failure
Received June 29, 2001; Revised August 17, 2001; Accepted October 23, 2001
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Q. Yu, R. Vazquez, E. V. Khojeini, C. Patel, R. Venkataramani, and D. F. Larson IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H76 - H85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Szalay, M. Sauter, M. Haberland, U. Zuegel, A. Steinmeyer, R. Kandolf, and K. Klingel Osteopontin: A Fibrosis-Related Marker Molecule in Cardiac Remodeling of Enterovirus Myocarditis in the Susceptible Host Circ. Res., April 10, 2009; 104(7): 851 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Swift, B. R. Gaume, K. M. Small, B. J. Aronow, and S. B. Liggett Differential coupling of Arg- and Gly389 polymorphic forms of the {beta}1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs Physiol Genomics, September 17, 2008; 35(1): 123 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rosenberg, C. Zugck, M. Nelles, C. Juenger, D. Frank, A. Remppis, E. Giannitsis, H. A. Katus, and N. Frey Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure Circ Heart Fail, May 1, 2008; 1(1): 43 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lenga, A. Koh, A. S. Perera, C. A. McCulloch, J. Sodek, and R. Zohar Osteopontin Expression Is Required for Myofibroblast Differentiation Circ. Res., February 15, 2008; 102(3): 319 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Deng, B. Kulle, M. Hosseini, G. Schluter, G. Hasenfuss, L. Wojnowski, and A. Schmidt Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity Eur J Heart Fail, October 1, 2007; 9(10): 986 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Satoh, M. Nakamura, T. Akatsu, Y. Shimoda, I. Segawa, and K. Hiramori Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy Eur J Heart Fail, August 1, 2005; 7(5): 755 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stawowy, C. Margeta, F. Blaschke, C. Lindschau, C. Spencer-Hansch, M. Leitges, G. Biagini, E. Fleck, and K. Graf Protein kinase C epsilon mediates angiotensin II-induced activation of {beta}1-integrins in cardiac fibroblasts Cardiovasc Res, July 1, 2005; 67(1): 50 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Graf and P. Stawowy Osteopontin: A Protective Mediator of Cardiac Fibrosis? Hypertension, December 1, 2004; 44(6): 809 - 810. [Full Text] [PDF]
|
|
|
|
|
|
R. Zohar, B. Zhu, P. Liu, J. Sodek, and C. A. McCulloch Increased cell death in osteopontin-deficient cardiac fibroblasts occurs by a caspase-3-independent pathway Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1730 - H1739. [Abstract] [Full Text] [PDF]
|
|